Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 17/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054712 | 0.87 | MAPT (0.68) | MAPTPKMLMNASMN1; SMN2HPGD | |
| SCHEMBL16284337 | 0.85 | HPGD (0.68) | MAPTLMNASMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL10061538 | 0.85 | MAPT (0.61) | MAPTPKMLMNASMN1; SMN2HPGD | |
| SCHEMBL16284338 | 0.84 | SIRT6 (0.68) | MAPTALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL10061540 | 0.84 | MAPT (0.60) | MAPTPKMLMNASMN1; SMN2HPGD | |
| SCHEMBL17919917 | 0.84 | MAPT (0.60) | MAPTPKMLMNASMN1; SMN2HPGD | |
| SCHEMBL18036523 | 0.83 | MAPT (0.75) | MAPTPKMLMNASMN1; SMN2HPGD | |
| SCHEMBL443596 | 0.82 | HPGD (0.73) | MAPTPKMLMNASMN1; SMN2HPGD | |
| SCHEMBL29788558 | 0.82 | HPGD (0.73) | MAPTPKMLMNASMN1; SMN2HPGD | |
| SCHEMBL22778043 | 0.81 | MAPT (0.79) | MAPTPKMLMNASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9832880-B2 | Electronic apparatus and method for manufacturing the same | Innolux Corporation (TW) | 2017-11-28 | — | — | US | disclosed |
| US-9428508-B2 | 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-08-30 | — | — | US | disclosed |
| US-20140362545-A1 | ELECTRONIC APPARATUS AND METHOD FOR MANUFACTURING THE SAME | Innolux Corporation (TW) | 2014-12-11 | — | — | US | disclosed |
| US-20140362545-A1 | ELECTRONIC APPARATUS AND METHOD FOR MANUFACTURING THE SAME | Innolux Corporation (TW) | 2014-12-11 | — | — | US | disclosed |
| US-20130281438-A1 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281438-A1 | 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS | PTK2B, PTK2, DAPK2 | MAPT 1164/4885PKM 652/4885LMNA 3388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.